Drug Patents owned by Anacor Pharms Inc

1. List of Eucrisa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8039451 ANACOR PHARMS INC Boron-containing small molecules
Jun, 2029

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8501712 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Feb, 2027

(4 years from now)

US9682092 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Feb, 2027

(4 years from now)

US8501712

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Aug, 2027

(4 years from now)

US9682092

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Aug, 2027

(4 years from now)

US8039451

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules
Dec, 2029

(6 years from now)

US8168614 ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Jan, 2030

(6 years from now)

US8168614

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules as anti-inflammatory agents
Jul, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Patient Population (NPP) Mar 23, 2023
Pediatric Exclusivity (PED) Jun 14, 2022

Drugs and Companies using CRISABOROLE ingredient

Market Authorisation Date: 14 December, 2016

Treatment: Method of treating mild to moderate atopic dermatitis.

Dosage: OINTMENT;TOPICAL

How can I launch a generic of EUCRISA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic